For Immediate Release
Chicago, IL – June 17, 2013 – Zacks Equity Research highlights Akamai (AKAM - Analyst Report)-Free Report) as the Bull of the Day and Barnes Group ((B - Snapshot Report)-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Varian Medical Systems, Inc. (VAR - Analyst Report)-Free Report), Siemens AG -Free Report) and Accuray Incorporated (ARAY - Analyst Report)-Free Report).
Here is a synopsis of all five stocks:
Bull of the Day:
If you've ever shopped online, downloaded music, watched a web video or connected to work remotely, you've probably used Akamai's (AKAM - Analyst Report)-Free Report) cloud platform. We ensure the best online experience on any device, anywhere.
Akamai helps enterprises accelerate innovation in the hyperconnected world by removing the complexities of technology so you can focus on driving your business faster forward. We enable enterprises to capitalize on market opportunities presented by trends like mobile and cloud while overcoming the challenges presented by security threats and the need to reach users globally.
The Akamai Intelligent Platform™ reaches globally and delivers locally, providing our customers with unmatched reliability, security and visibility into their online business.
Bear of the Day:
Sometimes you can have a good company that finds its stock a bit ahead of itself, which is what I think we are seeing here in Barnes Group, today’s Bear of the Day.
If you are not familiar, Barnes Group ((B - Snapshot Report)-Free Report) (Zacks Rank #5) is an international aerospace and industrial manufacturing and services provider, serving a wide range of end markets and customers. The products and services provided by the company are used in far-reaching applications that provide transportation, communication, manufacturing and technology to the world.
Many of their products are highly engineered, high quality (high price) products for those industries. In a world that is seeing slowing growth on the downswing rather than on the rise, I am concerned that the 50% rise in share price and 19 times earnings multiple might be a little rich. I have no doubt the company will continue to sell its components, but their growth looks questionable in the second quarter.
Barnes generates roughly 20% of its sales in Europe, 18% in Asia and 62% in the Americas.
Barnes Group reported Q1 adjusted earnings per share of 40 cents, up roughly 25% year over year in late April; the results fell 11.1% short of the Zacks Consensus Estimate for 45 cents.
Varian Links with Siemens Systems
Oncology and X-Ray products company Varian Medical Systems, Inc. (VAR - Analyst Report)-Free Report), and Siemens Healthcare, a part of Siemens AG -Free Report), recently revealed that technicians at The Ohio State University are utilizing Varian software to conduct radiotherapy sessions with linear accelerators manufactured by Siemens. The two companies have created an interface that links the Aria system from Varian with certain equipment of Siemens.
In Mar 2013, Siemens was granted 510(k) clearance from the Food and Drug Administration for connectivity between Aria software and two of its linear accelerators.
As per Varian, its software can function with 80% of Siemens hardware. In fact, a large proportion of Siemens locations may utilize Aria to handle different forms of care.
Siemens Healthcare is a leader in diagnostics, medical imaging and other health care areas. The company offers a wide range of offerings ranging from prevention to diagnosis.
Varian is a leading manufacturer of integrated radiotherapy systems for cancer treatment and a premier supplier of X-Ray tubes for diagnostic imaging applications. The company operates in a technology-driven environment where success depends on the use of new technology, product development and upgrades. In the radiation oncology market, Varian competes with Accuray Incorporated (ARAY - Analyst Report)-Free Report).
The company is poised to increase its market share in radiation oncology. It currently enjoys a healthy demand for its coveted TrueBeam technology, which has meaningfully contributed to its net order oncology growth. Varian’s TrueBeam is designed to treat tumors with beams of high speed and precision. It incorporates several technological innovations such as patient positioning and managing his/her motion. Given its high intensity nature, TrueBeam can dispense strong dosage over twice as fast as that possible with earlier equipment.
Get today’s Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on AKAM - FREE
Get the full Report on B - FREE
Get the full Report on VAR - FREE
Get the full Report on SI - FREE
Get the full Report on ARAY - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.